A systematic review on biological therapies in juvenile idiopathic inflammatory myopathies: an evidence gap in precision medicine

• Published in: Clinical and experimental rheumatology Vol. 40; no. 2; p. 457
• Main Authors: Marrani, Edoardo, Abu-Rumeileh, Sarah, Mastrolia, Maria Vincenza, Maccora, Ilaria, Pagnini, Ilaria, Simonini, Gabriele
• Format: Journal Article
• Language: English
• Published: Italy 01.02.2022
• Subjects: Adalimumab - therapeutic use; Adult; Antirheumatic Agents - therapeutic use; Biological Products - adverse effects; Biological Therapy; Child; Etanercept - therapeutic use; Humans; Infliximab - therapeutic use; Myositis - diagnosis; Myositis - drug therapy; Precision Medicine; Tumor Necrosis Factor Inhibitors - therapeutic use

Juvenile idiopathic inflammatory myopathies (JIIMs) are a heterogeneous group of systemic autoimmune diseases. Juvenile dermatomyositis (JDM) is the predominant form of JIIMs, and is a rare, chronic autoimmune illness characterised by symmetric, proximal muscle damages and involvement of the skin. I...